Evidence map›Paper›PMID 29345426›Full record

Trial reportESC heart failure2018

Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF).

Tee Joo Yeo, Poh Shuan Daniel Yeo, Farid Abdul Hadi, Timothy Cushway, Kim Yee Lee, Fang Fang Yin, Anne Ching, Ruili Li, Seet Yoong Loh, Shir Lynn Lim and 4 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESC heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 9 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 9 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Intravenous iron therapy for non-anaemic, iron-deficient adults.The Cochrane database of systematic reviews · 2019
    Pooled it
  10. Trial
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Iron Deficiency in Heart Failure: A Korea-Oriented Review.International journal of heart failure · 2023
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Tee Joo YeoNational University Heart Centre Singapore, National University Health System, 1E Kent Ridge Road, Level 9 Cardiac Department, NUHS Tower Block, 119228, Singapore.
Poh Shuan Daniel YeoTan Tock Seng Hospital, Singapore.
Farid Abdul HadiRoche Diagnostics Asia Pacific Pte Ltd, Singapore.
Timothy CushwayThe Iron Suites, Singapore.
Kim Yee LeeNational University Heart Centre Singapore, National University Health System, 1E Kent Ridge Road, Level 9 Cardiac Department, NUHS Tower Block, 119228, Singapore.
Fang Fang YinTan Tock Seng Hospital, Singapore.
Anne ChingNational University Heart Centre Singapore, National University Health System, 1E Kent Ridge Road, Level 9 Cardiac Department, NUHS Tower Block, 119228, Singapore.
Ruili LiTan Tock Seng Hospital, Singapore.
Seet Yoong LohTan Tock Seng Hospital, Singapore.
Shir Lynn LimNational University Heart Centre Singapore, National University Health System, 1E Kent Ridge Road, Level 9 Cardiac Department, NUHS Tower Block, 119228, Singapore.
Raymond Ching-Chiew WongNational University Heart Centre Singapore, National University Health System, 1E Kent Ridge Road, Level 9 Cardiac Department, NUHS Tower Block, 119228, Singapore.
Bee Choo TaiSaw Swee Hock School of Public Health, National University of Singapore, Singapore.
Arthur Mark RichardsNational University Heart Centre Singapore, National University Health System, 1E Kent Ridge Road, Level 9 Cardiac Department, NUHS Tower Block, 119228, Singapore.
Carolyn S P LamNational Heart Centre, Singapore and Duke-National University of Singapore, Singapore.
National University Health System · SGTan Tock Seng Hospital · SGNational University Heart Centre Singapore · SGNational University of Singapore · SGAdaptations Glassware Cooperative · USIron Mountain (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsIron deficiency is highly prevalent in Southeast Asians with heart failure (HF) and associated with worse outcomes. This trial aimed to assess the effect of intravenous iron in Southeast Asians hospitalized with decompensated HF. METHODS AND

resultsFifty patients hospitalized for acute decompensated HF, regardless of ejection fraction, with iron deficiency (defined as serum ferritin <300 ng/mL if transferrin saturation is <20%) were randomized to receive either one dose of intravenous ferric carboxymaltose (FCM) 1000 mg or placebo (0.9% saline) following HF stabilization and before discharge in two Singapore tertiary centres. The primary endpoint was difference in 6-min walk test (6MWT) distance over 12 weeks, while secondary endpoints were quality of life assessed using validated Kansas City Cardiomyopathy Questionnaire (KCCQ) and Visual Analogue Scale (VAS). Improvement in 6MWT distance at Week 12 was observed in both FCM and placebo groups (from 252 ± 123 to 334 ± 128 m and from 243 ± 67 to 301 ± 83 m, respectively). Unadjusted analysis showed 6MWT distance for FCM exceeded that for placebo, but adjustment for baseline covariates and time attenuated this effect {adjusted mean difference between groups: 0.88 m [95% confidence interval (CI) -30.2 to 32.0, P = 0.956]}. KCCQ overall summary and VAS were similar in both groups [adjusted mean difference: KCCQ -1.48 (95% CI -8.27 to 5.31, P = 0.670) and VAS 0.26 (95% CI -0.33 to 0.86, P = 0.386)]. FCM was well tolerated with no serious treatment-related adverse events.

conclusionsIntravenous FCM administered pre-discharge in Southeast Asians hospitalized with decompensated HF is clinically feasible. Changes in 6MWT distance should be measured beyond Week 12 to account for background therapy effects.

Indexed as

Anemia, Iron-DeficiencyDose-Response Relationship, DrugDouble-Blind MethodFemaleFerric CompoundsFollow-Up StudiesHeart FailureHumansInjections, IntravenousIronMaleMaltoseMiddle AgedPilot ProjectsPrevalenceRetrospective Studiesferric carboxymaltoseFerric CompoundsIronMaltoseFerric carboxymaltoseIron deficiencySoutheast Asian heart failure

Identifiers

PMID29345426
PMCPMC5880664
OpenAlexW2789583640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.